research use only

Ketohexokinase inhibitor 1 Carbohydrate Metabolism inhibitor

Cat.No.S0808

Ketohexokinase inhibitor 1 (PF-06835919, MDK1846) is a potent inhibitor of ketohexokinase (KHK) with IC50 of 8.4 nM and 66 nM for KHK-C and KHK-A, respectively.
Ketohexokinase inhibitor 1 Carbohydrate Metabolism inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 356.34

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 356.34 Formula

C16H19F3N4O2

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2102501-84-6 -- Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 71 mg/mL ( (199.24 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 71 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04427917 Completed
Healthy
Pfizer
November 24 2020 Phase 1
NCT04193436 Completed
Hepatic Impairment|Healthy Participants
Pfizer
January 21 2020 Phase 1
NCT02974374 Completed
Non-alcoholic Fatty Liver Disease
Pfizer
October 2016 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.